Plasmablastic lymphoma associated to Crohn's disease and hepatitis C virus chronic infection

Journal of Crohn's and Colitis

Volumn 5, Issue 6, 2011, Pages 628-632

  Plaza, Rocio ^a   Ponferrada, Angel ^a   Benito, Dulce M ^a   Arevalo, Noelia ^a   Foncillas, Maria Angeles ^a   De Fuenmayor, Maria Luisa ^a   Aldeguer, Mercedes ^a  

^a HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

Author keywords

Anti TNF; Crohn's disease; Hepatitis c virus; Immunomodulators; Plasmablastic lymphoma

Indexed keywords

ALPHA FETOPROTEIN; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; INFLIXIMAB; ISONIAZID; KI 67 ANTIGEN; PRIMIDONE; SYNDECAN 1; VINCRISTINE; VIRUS ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CASE REPORT; CIGARETTE SMOKING; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOMEGALOVIRUS; DEATH; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELASTOGRAPHY; EPILEPSY; EPSTEIN BARR VIRUS; FECES ANALYSIS; FEMALE; FOLLOW UP; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; ILEOSTOMY; IMMUNOHISTOCHEMISTRY; INTESTINE ENDOSCOPY; LEUKOCYTE COUNT; LIVER FIBROSIS; LIVER METASTASIS; LYMPHADENOPATHY; LYMPHOMA; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMABLASTIC LYMPHOMA; PRIORITY JOURNAL; SEROLOGY; SUPPURATION; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT FAILURE; TUBERCULIN TEST; ULCERATIVE COLITIS; VIRUS GENE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZATHIOPRINE; CROHN DISEASE; FATAL OUTCOME; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED;

EID: 82255162856     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.07.002     Document Type: Article

References (22)

1. Thayu M., Markowitz J.E., Mamula P., Russo P.A., Muinos W.I., Baldassano R.N. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn's disease. J Pediatr Gastroenterol Nutr 2005, 40:220-222.
2. Rosh J.R., Gross T., Mamula P., Griffiths A., Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?. Inflamm Bowel Dis Aug. 2007, 13(8):1024-1030.
3. Tan L.H. A practical approach to the understanding and diagnosis of lymphoma: an assessment of the WHO classification based on immunoarchitecture and immuno-ontogenic principles. Pathology 2009, 41(4):305-326.
4. Suzuki Y., Yoshida T., Nakamura N., Kamata H., Kotani S., Ohsaka M., Kajita S., Miyazaki K., Ohtani S., Nakayama M., Horie R., Hayakawa K., Niitsu N., Higashihara M. CD3 and CD4 positive plasmablastic lymphoma: a literature review of Japanese plasmablastic lymphoma cases. Intern Med 2010, 49(16):1801-1805.
5. Hatanaka K., Namakura N., Kishimoto K., Sugino K., Uekusa T. Plasmablastic lymphoma of the cecum: report of a case with cytologic findings. Diagn Cytopathol 2011 Apr, 39(4):297-300.
6. Lim J.H., Lee M.H., Lee M.J., Kim C.S., Lee J.S., Choi S.J., Yi H.G. Plasmablastic lymphoma in the anal canal. Cancer Res Treat Sep. 2009, 41(3):182-185.
7. Redmond M., Quinn J., Murphy P., Patchett S., Leader M. Plasmablastic lymphoma presenting as a paravertebral mass in a patient with Crohn's disease after immunosuppressive therapy. J Clin Pathol Jan. 2007, 60(1):80-818.
8. Bewtra M., Lewis J.D. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol 2010, 6(4):621-631.
9. Jones J., Loftus E.V. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?. Inflamm Bowel Dis 2007, 13:1299-1307.
10. Beaugerie L., Brousse N., Bouvier A.M., Colombel J.F., Lémann M., Cosnes J., Hébuterne X., Cortot A., Bouhnik Y., Gendre J.P., Simon T., Maynadié M., Hermine O., Faivre J., Carrat F. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet Nov. 7 2009, 374(9701):1617-1625. CESAME Study Group.
11. Armstrong R.G., West J., Card T.R. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol Jul. 2010, 105(7):1604-1609.
12. Lichtenstein G.R., Cohen R.D., Feagan B.G., Sandborn W.J., Salzberg B.A., Chen D.M., Pritchard M., Broussard D., Diamond R. Safety of infliximab and other Crohn's disease therapies - Treat Registry Data with nearly 15,000 patient-years of follow-up. Gastroenterology 2006, 130(Suppl 2):A-71.
13. Siegel C.A., Marden S.M., Persing S.M., Larson R.J., Sands B. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of crohn's disease: a meta-analysis. E. I Clin Gastroenterol Hepatol 2009 August, 7(8):874-881.
14. Sokol H., Seksik P., Carrat F., Nion-Larmurier I., Vienne A., Beaugerie L., Cosnes J. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut Oct. 2010, 59(10):1363-1368.
15. de Sanjose S., Benavente Y., Vajdic C.M., Engels E.A., Morton L.M., Bracci P.M., Spinelli J.J., Zheng T., Zhang Y., Franceschi S., Talamini R., Holly E.A., Grulich A.E., Cerhan J.R., Hartge P., Cozen W., Boffetta P., Brennan P., Maynadié M., Cocco P., Bosch R., Foretova L., Staines A., Becker N., Nieters A. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol Apr. 2008, 6(4):451-458.
16. Mele A., Pulsoni A., Bianco E., Musto P., Szklo A., Sanpaolo M.G., Iannitto E., De Renzo A., Martino B., Liso V., Andrizzi C., Pusterla S., Dore F., Maresca M., Rapicetta M., Marcucci F., Mandelli F., Franceschi S. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003, 102(3):996-999.
17. Duberg A.S., Nordström M., Törner A., Reichard O., Strauss R., Janzon R., Bäck E., Ekdahl K. Non-Hodgkin's lymphom and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 2005 Mar, 41(3):652-659.
18. Marcucci F., Mele A., Esteve Hepatitis viruses and non-Hodgkin lymphoma:epidemiology, mechanisms of tumorigenesis and therapeutic opportunities. Blood 2011 Feb 10, 117(6):1792-1798.
19. Sugawara Y., Makuuchi M., Kato N., Shimotohno K., Takada K. Enhancement of hepatitis C virus replication by Epstein-Barr virus-encoded nuclear antigen 1. EMBO J 1999, 18(20):5755-5760.
20. Dayharsh G.A., Loftus E.V., Sandborn W.J., Tremaine W.J., Zinsmeister A.R., Witzig T.E., Macon W.R., Burgart L.J. Epstein-Barr viruspositive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002, 122:72-77.
21. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., Domènech E., Eliakim R., Eser A., Frater J., Gassull M., Giladi M., Kaser A., Lémann M., Moreels T., Moschen A., Pollok R., Reinisch W., Schunter M., Stange E.F., Tilg H., Van Assche G., Viget N., Vucelic B., Walsh A., Weiss G., Yazdanpanah Y., Zabana Y., Travis S.P., Colombel J.F. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis Jun. 2009, 3(2):47-91. on behalf of the European Crohn's and Colitis Organisation (ECCO).
22. Gisbert J.P., Chaparro M., Esteve Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011 Mar, 33(6):619-633.